Background: Provision of opioid agonist treatment (OAT) in custodial settings is resource-intensive and may be associated with diversion, non-medical use, and violence. A clinical trial of a new OAT, depot buprenorphine (the UNLOC-T study), provided the opportunity to obtain health and correctional staff perspectives regarding this treatment prior to widespread roll-out.
Methods: Sixteen focus groups with 52 participants were conducted, including 44 health staff (nurses, nurse practitioners, doctors, and operational staff) and eight correctional staff.
Results: Key challenges to providing OAT identified as potentially being addressed by depot buprenorphine included 1) patient access, 2) OAT program capacity, 3) treatment administration procedures, 4) medication diversion and other safety issues and, 5) impact on other service delivery.
Conclusions: The introduction of depot buprenorphine into correctional settings was considered to have the potential to increase safety for patients, improve staff / patient relations and advance patient health outcomes via expanded treatment coverage and efficiencies gained through enhanced health service delivery. Support was almost universal from both correctional and health staff participating in this study. These findings build on emerging research regarding the positive impact of more flexible OAT programs and could be used to engage support for the implementation of depot buprenorphine from staff in other secure settings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drugpo.2023.103978 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buprenorphine Salivary Gland Accumulation Sustaining High Oral Fluid Exposure and Increasing the Risk of Streptococcus mutans Biofilm Formation.
J Addict Med
December 2024
From the Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX (ZZ, JC, SS, VTŠ, TY, RS, MH); School of Dentistry, University of Texas Health Science Center at Houston, TX (BW).
Objectives: The US Food and Drug Administration (FDA) issued a warning about buprenorphine-induced dental caries of unknown mechanism in 2022. To investigate the potential mechanism, the association between local buprenorphine exposure and dental biofilm formation will be explored in this study.
Methods: Female F344 rats were dosed with sublingual buprenorphine film or intravenous injection to explore the oral cavity exposure of the buprenorphine.
Initiation of buprenorphine in the emergency department or emergency out-of-hospital setting: A mixed-methods systematic review.
Am J Emerg Med
November 2024
Department of Paramedicine, School of Primary and Allied Health Care, Faculty of Medicine, Nursing, and Health Sciences, Monash University, Victoria, Australia.
Introduction: People who use substances increasingly access healthcare primarily through emergency medical services (EMS) and emergency departments (EDs). To meet the needs of these patients, EMS and EDs have become access points for medications for opioid use disorder (OUD), specifically buprenorphine. This systematic review aimed to quantify the efficacy of these programs, examining retention in treatment for OUD, rates of re-presentation to ED or EMS, and rates of precipitated withdrawal, as well as summarise clinician and patient perspectives on buprenorphine initiation in these settings.
View Article and Find Full Text PDFEfficacy of Transdermal Buprenorphine Patch in Postoperative Pain Management in Oral and Maxillofacial Surgery.
J Maxillofac Oral Surg
October 2024
Department of Oral Maxillofacial Surgery, Vydehi Institute of Dental Sciences, #82 EPIP Zone, Near BTMC 18th Depot, Vijayanagar, Whitefield, Bangalore, 560066 India.
Article Synopsis
- The study aimed to assess the effectiveness of transdermal Buprenorphine patches in managing postoperative pain following major oral and maxillofacial surgeries done under general anesthesia, involving 100 participants aged 18-60.! -
- Results showed that the average pain score (measured via a visual analogue scale) was lower in males (3.9) compared to females (4.4), with a significant proportion of trauma patients requiring fewer additional analgesics than those with other pathologies.! -
- The study concluded that Buprenorphine patches provide a high level of pain relief, are cost-effective, improve patient compliance, and have fewer side effects, making them a promising option for postoperative pain management.!
Switch from methadone to buprenorphine with microinduction in outpatient setting.
Tidsskr Nor Laegeforen
September 2024
Klinikk psykisk helse og avhengighet, Sykehuset i Vestfold, Tønsberg.
Background: Switching from methadone to buprenorphine in patients receiving opioid maintenance therapy often requires inpatient care with a gradual tapering of methadone and an opioid-free day with challenging withdrawal symptoms. This case report describes and discusses a gentle outpatient approach without the opioid-free day.
Case Presentation: A patient with a 15-year history of opioid maintenance therapy reduced his methadone dose from 80 mg to 50 mg due to concurrent use of other sedative substances and a significant risk of overdose.
[Challenges in the treatment of opioid dependence].
Nervenarzt
September 2024
LVR-Universitätsklinik Essen, Klinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Universität Duisburg-Essen, Essen, Deutschland.
Background: The number of persons using opioids has increased worldwide in the last decade, particularly the use of opioid analgesics in North America and Africa. In Germany, the prevalence of heroin addiction has remained relatively stable.
Method: Narrative review of the literature.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!